Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae

Detalhes bibliográficos
Autor(a) principal: Ferreira, André C.
Data de Publicação: 2017
Outros Autores: Valle, Camila Zaverucha do, Reis, Patricia Alves, Lima, Giselle Barbosa, Vieira, Yasmine Rangel, Mattos, Mayara, Silva, Priscila de Paiva, Sacramento, Carolina, Faria Neto, Hugo C. de Castro, Campanati, Loraine, Tanuri, Amilcar, Brüning, Karin, Bozza, Fernando A., Bozza, Patrícia Torres, Souza, Thiago Moreno L.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/22840
Resumo: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.
id CRUZ_a64854d80bc4bc6c0a103492ce7e1853
oai_identifier_str oai:www.arca.fiocruz.br:icict/22840
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Ferreira, André C.Valle, Camila Zaverucha doReis, Patricia AlvesLima, Giselle BarbosaVieira, Yasmine RangelMattos, MayaraSilva, Priscila de PaivaSacramento, CarolinaFaria Neto, Hugo C. de CastroCampanati, LoraineTanuri, AmilcarBrüning, KarinBozza, Fernando A.Bozza, Patrícia TorresSouza, Thiago Moreno L.2017-10-17T13:16:07Z2017-10-17T13:16:07Z2017FERREIRA, André C. et al. Sofosbuvir protects Zika virusinfected mice from mortality, preventing short- and long-term sequelae. Scientifc Reports, v.7:9409, 9p, Aug. 2017.2045-2322https://www.arca.fiocruz.br/handle/icict/2284010.1038/s41598-017-09797-8engNature Publishing GroupZika VirusSofosbuvirmedicamentos antiviraisSequelasPrevençãoZika virusSofosbuvirsequelaeantiviral drugspreventionSofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelaeinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.Universidade Federal do Rio de Janeiro. Instituto de Ciências Biomédicas. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Instituto de Biologia. Rio de Janeiro, RJ, BrasilBMK Consortium: Blanver Farmoquímica Ltda; Microbiológica Química e Farmacêutica Ltda, Karin Bruning & Cia. Ltda. Taboão da Serra, SP, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas. Rio de Janeiro, RJ, Brasil.Zika virus (ZIKV) causes significant public health concerns because of its association with congenital malformations, neurological disorders in adults, and, more recently, death. Considering the necessity to mitigate ZIKV-associated diseases, antiviral interventions are an urgent necessity. Sofosbuvir, a drug in clinical use against hepatitis C virus (HCV), is among the FDA-approved substances endowed with anti-ZIKV activity. In this work, we further investigated the in vivo activity of sofosbuvir against ZIKV. Neonatal Swiss mice were infected with ZIKV (2 × 10(7) PFU) and treated with sofosbuvir at 20 mg/kg/day, a concentration compatible with pre-clinical development of this drug. We found that sofosbuvir reduced acute levels of ZIKV from 60 to 90% in different anatomical compartments, such as the blood plasma, spleen, kidney, and brain. Early treatment with sofosbuvir doubled the percentage and time of survival of ZIKV-infected animals. Sofosbuvir also prevented the acute neuromotor impairment triggered by ZIKV. In the long-term behavioural analysis of ZIKV-associated sequelae, sofosbuvir prevented loss of hippocampal- and amygdala-dependent memory. Our results indicate that sofosbuvir inhibits ZIKV replication in vivo, which is consistent with the prospective necessity of antiviral drugs to treat ZIKV-infected individuals.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/22840/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALandre_ferreira_etal_IOC_2017.pdfandre_ferreira_etal_IOC_2017.pdfapplication/pdf1574700https://www.arca.fiocruz.br/bitstream/icict/22840/2/andre_ferreira_etal_IOC_2017.pdf1cbe13c85078c5cb11c6954145f48296MD5241598_2017_9797_MOESM1_ESM.pdf41598_2017_9797_MOESM1_ESM.pdfMaterial Suplementarapplication/pdf363612https://www.arca.fiocruz.br/bitstream/icict/22840/3/41598_2017_9797_MOESM1_ESM.pdfafff57fb33544557851bb96a0b2fe764MD5341598_2017_9797_MOESM2_ESM.mov41598_2017_9797_MOESM2_ESM.movMaterial Suplementarvideo/quicktime3163291https://www.arca.fiocruz.br/bitstream/icict/22840/4/41598_2017_9797_MOESM2_ESM.mov6272b4d88b5fe0d20ce993fc999b24c7MD54TEXTandre_ferreira_etal_IOC_2017.pdf.txtandre_ferreira_etal_IOC_2017.pdf.txtExtracted texttext/plain40600https://www.arca.fiocruz.br/bitstream/icict/22840/5/andre_ferreira_etal_IOC_2017.pdf.txt61aee28f45a27059e55b6c88e6093dcfMD5541598_2017_9797_MOESM1_ESM.pdf.txt41598_2017_9797_MOESM1_ESM.pdf.txtExtracted texttext/plain2165https://www.arca.fiocruz.br/bitstream/icict/22840/6/41598_2017_9797_MOESM1_ESM.pdf.txt3f8c15ec6761ab50df36a193edbe1db6MD56icict/228402023-09-04 11:10:47.429oai:www.arca.fiocruz.br:icict/22840Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-09-04T14:10:47Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
title Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
spellingShingle Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
Ferreira, André C.
Zika Virus
Sofosbuvir
medicamentos antivirais
Sequelas
Prevenção
Zika virus
Sofosbuvir
sequelae
antiviral drugs
prevention
title_short Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
title_full Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
title_fullStr Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
title_full_unstemmed Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
title_sort Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
author Ferreira, André C.
author_facet Ferreira, André C.
Valle, Camila Zaverucha do
Reis, Patricia Alves
Lima, Giselle Barbosa
Vieira, Yasmine Rangel
Mattos, Mayara
Silva, Priscila de Paiva
Sacramento, Carolina
Faria Neto, Hugo C. de Castro
Campanati, Loraine
Tanuri, Amilcar
Brüning, Karin
Bozza, Fernando A.
Bozza, Patrícia Torres
Souza, Thiago Moreno L.
author_role author
author2 Valle, Camila Zaverucha do
Reis, Patricia Alves
Lima, Giselle Barbosa
Vieira, Yasmine Rangel
Mattos, Mayara
Silva, Priscila de Paiva
Sacramento, Carolina
Faria Neto, Hugo C. de Castro
Campanati, Loraine
Tanuri, Amilcar
Brüning, Karin
Bozza, Fernando A.
Bozza, Patrícia Torres
Souza, Thiago Moreno L.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ferreira, André C.
Valle, Camila Zaverucha do
Reis, Patricia Alves
Lima, Giselle Barbosa
Vieira, Yasmine Rangel
Mattos, Mayara
Silva, Priscila de Paiva
Sacramento, Carolina
Faria Neto, Hugo C. de Castro
Campanati, Loraine
Tanuri, Amilcar
Brüning, Karin
Bozza, Fernando A.
Bozza, Patrícia Torres
Souza, Thiago Moreno L.
dc.subject.other.pt_BR.fl_str_mv Zika Virus
Sofosbuvir
medicamentos antivirais
Sequelas
Prevenção
topic Zika Virus
Sofosbuvir
medicamentos antivirais
Sequelas
Prevenção
Zika virus
Sofosbuvir
sequelae
antiviral drugs
prevention
dc.subject.en.pt_BR.fl_str_mv Zika virus
Sofosbuvir
sequelae
antiviral drugs
prevention
description Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ. Brasil.
publishDate 2017
dc.date.accessioned.fl_str_mv 2017-10-17T13:16:07Z
dc.date.available.fl_str_mv 2017-10-17T13:16:07Z
dc.date.issued.fl_str_mv 2017
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv FERREIRA, André C. et al. Sofosbuvir protects Zika virusinfected mice from mortality, preventing short- and long-term sequelae. Scientifc Reports, v.7:9409, 9p, Aug. 2017.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/22840
dc.identifier.issn.pt_BR.fl_str_mv 2045-2322
dc.identifier.doi.none.fl_str_mv 10.1038/s41598-017-09797-8
identifier_str_mv FERREIRA, André C. et al. Sofosbuvir protects Zika virusinfected mice from mortality, preventing short- and long-term sequelae. Scientifc Reports, v.7:9409, 9p, Aug. 2017.
2045-2322
10.1038/s41598-017-09797-8
url https://www.arca.fiocruz.br/handle/icict/22840
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/22840/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/22840/2/andre_ferreira_etal_IOC_2017.pdf
https://www.arca.fiocruz.br/bitstream/icict/22840/3/41598_2017_9797_MOESM1_ESM.pdf
https://www.arca.fiocruz.br/bitstream/icict/22840/4/41598_2017_9797_MOESM2_ESM.mov
https://www.arca.fiocruz.br/bitstream/icict/22840/5/andre_ferreira_etal_IOC_2017.pdf.txt
https://www.arca.fiocruz.br/bitstream/icict/22840/6/41598_2017_9797_MOESM1_ESM.pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
1cbe13c85078c5cb11c6954145f48296
afff57fb33544557851bb96a0b2fe764
6272b4d88b5fe0d20ce993fc999b24c7
61aee28f45a27059e55b6c88e6093dcf
3f8c15ec6761ab50df36a193edbe1db6
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008910018150400

Registros relacionados